Adjunct Instructor, Roybal Laboratory
Department of Medicine, Division of Hematology and Oncology
Dr. Draper specializes in the treatment of patients with recurrent ovarian cancer using systemic therapies, including chemotherapy and immunotherapy. She is committed to evaluating and offering clinical trial opportunities as part of individualized patient care.
| Year | Institution & Location | Degree | Field of Study |
|---|---|---|---|
| 2010 | Juniata College, Huntingdon, PA | B.S. | Biology |
| 2017 |
University of Maryland School of Medicine, Baltimore, Maryland |
M.D. |
Medicine |
| 2022 | The Mount Sinai Hospital, New York, New York | Residency |
Internal Medicine |
| 2025 | University of California San Francisco, San Francisco, California | Fellowship |
Medical Oncology |
|
2025 - 2027 2025 - 2026 2024 - 2025 2024 |
Parker Institute for Cancer Immunotherapy Early Career Research Award: Parker Scholar Gladstone-UCSF Institute of Genomic Immunology Symbiont Seed Grant: “Antigen Discovery for Ovarian Cancer” 2024 Conquer Cancer Young Investigator Award, American Society of Clinical Oncology 2024 Women in Cancer Immunotherapy Network Leadership Institute Selected Participant, Society for Immunotherapy of Cancer |
|
2023 - 2025 |
Physician-Scientist Fellow, Chan Zuckerberg Biohub - San Francisco |
Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, Rae Z, Achar SR, Altan-Bonnet G, Zhang L, Wu X, Meyer TJ, Kelly MC, Taylor N, Hinrichs CS, Ishii K. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. Sci Adv. 2025 Apr 11;11(15). PMCID: PMC11980841.
Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018 Apr 19;3(8) PubMed Central PMCID: PMC5931134.
Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res. 2015 Oct 1;21(19):4431-9. PubMed Central PMCID: PMC4603283.
Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10;33(14):1543-50. PubMed Central PMCID: PMC4417725.